Mer­ck halts en­roll­ment on two PhI­II Keytru­da com­bo stud­ies as out­side mon­i­tors flag a wor­ry­ing rate of deaths

Mer­ck $MRK has had to hit the brakes on en­rolling new pa­tients for two of its late-stage com­bo stud­ies in­volv­ing its block­buster check­point Keytru­da af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.